sonar-pro
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.
{
  "id": "0a0a5762-6b02-471a-8078-10027e2bee18",
  "choices": [
    {
      "finish_reason": "stop",
      "index": 0,
      "logprobs": null,
      "message": {
        "content": "{\"answer\":\"NO\",\"note\":\"Laos is classified under WHO climatic Zone IV (hot and humid), for which the recommended long-term stability study conditions are 30°C/65% RH or 30°C/75% RH, not 25°C/60% RH. Submission of stability data at 25°C/60% RH, even if supported by accelerated studies, does not meet the standard long-term requirements for Zone IV countries like Laos. Each country determines its sub-zone (IVa or IVb), but 25°C/60% RH is not considered appropriate for long-term stability for pharmaceutical products in Laos[1][2][3].\"}",
        "refusal": null,
        "role": "assistant",
        "annotations": null,
        "audio": null,
        "function_call": null,
        "tool_calls": null
      },
      "delta": {
        "role": "assistant",
        "content": ""
      }
    }
  ],
  "created": 1755743685,
  "model": "sonar-pro",
  "object": "chat.completion",
  "service_tier": null,
  "system_fingerprint": null,
  "usage": {
    "completion_tokens": 134,
    "prompt_tokens": 31,
    "total_tokens": 165,
    "completion_tokens_details": null,
    "prompt_tokens_details": null,
    "search_context_size": "low",
    "cost": {
      "input_tokens_cost": 0.0,
      "output_tokens_cost": 0.002,
      "request_cost": 0.006,
      "total_cost": 0.008
    }
  },
  "citations": [
    "https://www.pharmoutsourcing.com/Featured-Articles/37672-Regulatory-Strategy-for-Long-Term-Stability-Conditions-to-Support-Submission-in-Zone-IV-Countries/",
    "https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf",
    "http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf",
    "https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf",
    "https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf"
  ],
  "search_results": [
    {
      "title": "Regulatory Strategy for Long-Term Stability Conditions to Support ...",
      "url": "https://www.pharmoutsourcing.com/Featured-Articles/37672-Regulatory-Strategy-for-Long-Term-Stability-Conditions-to-Support-Submission-in-Zone-IV-Countries/",
      "date": "2011-03-01",
      "last_updated": "2025-08-21"
    },
    {
      "title": "[PDF] Annex 10 - ICH",
      "url": "https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    },
    {
      "title": "[PDF] Annex 2 Stability testing of active pharmaceutical ingredients and ...",
      "url": "http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    },
    {
      "title": "[PDF] Q 1 A (R2) Stability Testing of new Drug Substances and Products",
      "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    },
    {
      "title": "[PDF] Annex 2 Stability testing of active pharmaceutical ingredients and ...",
      "url": "https://www.rsc.org/suppdata/c5/ra/c5ra07716h/c5ra07716h1.pdf",
      "date": null,
      "last_updated": "2025-03-27"
    }
  ]
}